Skyclarys Access Battle in Ireland | Ireland News
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
Friedreich’s ataxia patients are fighting for access to the breakthrough drug Skyclarys, approved in the U.S. and Europe, which could slow disease progression by up to 55%. Ireland’s HSE has refused to fund it due to uncertainty over its effectiveness, sparking fierce political pressure from both parties and patient advocates. Biogen is being urged to collaborate with the HSE and consider a compassionate access program before the August 25th meeting — as families await a lifeline that may not cure, but could dramatically improve their quality of life.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/aedff387ab617632